Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Oncology

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2009.27.2419PMID 20805453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines

  2010cited by this paper
• Gene-expression signatures in breast cancer.

  2009cited by this paper
• T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

  2009cited by this paper
• Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

  2009cited by this paper
• Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome

  2008cited by this paper
• The humoral immune system has a key prognostic impact in node-negative breast cancer.

  2008cited by this paper
• The fibromatosis signature defines a robust stromal response in breast carcinoma

  2008cited by this paper
• Stromal gene expression predicts clinical outcome in breast cancer

  2008cited by this paper
• Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?

  2008cited by this paper
• Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

  2007cited by this paper
• An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

  2007cited by this paper
• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  2007cited by this paper
• Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

  2007cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

  2006cited by this paper
• Dichotomizing continuous predictors in multiple regression: a bad idea

  2006cited by this paper
• Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

  2006cited by this paper
• Fibroblasts in cancer

  2006cited by this paper
• Laser microdissection and microarray analysis of breast tumors reveal ER-α related genes and pathways

  2006cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Controlling the number of false discoveries: application to high-dimensional genomic data

  2004cited by this paper
• Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

  2004cited by this paper
• Friends or foes — bipolar effects of the tumour stroma in cancer

  2004cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

  2003cited by this paper
• Basement membranes: structure, assembly and role in tumour angiogenesis

  2003cited by this paper
• Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

  2003cited by this paper
• Naturally occurring B-cell responses to breast cancer

  2003cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Tumors are unique organs defined by abnormal signaling and context.

  2001cited by this paper
• Putting tumours in context

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma.

  1997cited by this paper
• Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas.

  1997cited by this paper
• Lymphocyte infiltrates as a prognostic variable in female breast cancer.

  1992cited by this paper
• Density of lymphocytic infiltration of primary breast cancer does not affect short-term disease-free interval or survival.

  1990cited by this paper
• Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma in vitro.

  1975cited by this paper
• * Joint first authors

  year unknowncited by this paper

• The interplay between cytokines and immune checkpoints in breast cancer therapy.

  2026cites this paper
• Exploring the Role of APC in Modulating Chemotherapeutic Response in Triple-Negative Breast Cancer cells

  2026cites this paper
• Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer

  2025cites this paper
• Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneity

  2025cites this paper
• Spatial Localization of Collagen Hydroxylated Proline Site Variation as an Ancestral Trait in the Breast Cancer Microenvironment.

  2025cites this paper
• The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer

  2025cites this paper
• Review of Breast Cancer Datasets and Repositories: Emphasis on Longitudinal Component

  2025cites this paper
• Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma

  2025cites this paper
• Survival Analysis of TNBC Subtype Breast Cancer Based on Clinicopathology at Prof. Dr. I.G.N.G Ngoerah Hospital Denpasar

  2024cites this paper
• Development and validation of a gene expression-based Breast Cancer Purity Score

  2024cites this paper
• Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer

  2023cites this paper
• Construction of a prognostic model for triple‐negative breast cancer based on immune‐related genes, and associations between the tumor immune microenvironment and immunological therapy

  2023cites this paper
• The PD-1 single‐nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient

  2023cites this paper
• Annotated Compendium of 102 Breast Cancer Gene-Expression Datasets

  2023cites this paper
• Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer

  2023cites this paper
• Combining the guidelines and multiphoton imaging methods to improve the prognostic value of tumor‐infiltrating lymphocytes in breast cancer

  2023cites this paper
• A Comprehensive Landscape of Imaging Feature-Associated RNA Expression Profiles in Human Breast Tissue

  2023cites this paper
• Defined extracellular matrix compositions support stiffness-insensitive cell spreading and adhesion signaling

  2023cites this paper
• Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies

  2023cites this paper
• Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy

  2023cites this paper
• Prognostic Impact of CD38- and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer

  2023cites this paper
• Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer

  2022cites this paper
• Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice

  2022cites this paper
• Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature

  2022cites this paper
• PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer

  2022cites this paper
• Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer

  2022cites this paper
• Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer.

  2022cites this paper
• The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets

  2022cites this paper
• Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival

  2022cites this paper
• Gene Expression Profiling in Early Breast Cancer—Patient Stratification Based on Molecular and Tumor Microenvironment Features

  2022cites this paper
• Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer

  2022cites this paper
• A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer

  2022cites this paper
• Can granulysin provide prognostic value in primary breast cancer?

  2022cites this paper
• Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer

  2021cites this paper
• Artificial Intelligence toward Personalized Medicine

  2021cites this paper
• Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

  2021cites this paper
• Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies

  2021cites this paper
• Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice

  2021cites this paper
• Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery

  2021cites this paper
• Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

  2021cites this paper
• Meta-Analysis of Microdissected Breast Tumors Reveals Genes Regulated in the Stroma but Hidden in Bulk Analysis

  2021cites this paper
• Identification of gastric cancer subtypes based on pathway clustering

  2021cites this paper
• Interleukin-17-based cytokine signaling as a determinant for tumor immune microenvironment with prognostic value in triple-negative breast cancer

  2021cites this paper
• Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer

  2021cites this paper
• Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

  2021cites this paper
• Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

  2021cites this paper
• A Four-Gene Signature in the Tumor Microenvironment That Significantly Associates with the Prognosis of Patients with Breast Cancer.

  2020cites this paper
• A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

  2020cites this paper
• Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer

  2020cites this paper
• HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers

  2020cites this paper
• Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer

  2020cites this paper
• Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers

  2020cites this paper
• Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients

  2020cites this paper
• Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer

  2020cites this paper
• Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients

  2020cites this paper
• Development of an Immune-Related Prognostic Signature in Breast Cancer

  2020cites this paper
• BTF3 promotes stemness and inhibits TypeⅠInterferon signaling pathway in triple-negative breast cancer.

  2020cites this paper
• Transcriptome analysis of tongue cancer based on high-throughput sequencing

  2020cites this paper
• Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs)

  2020cites this paper
• Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy

  2020cites this paper
• Hilda Vihervuori TUMOR-INFILTRATING LYMPHOCYTES AND CD8+ T CELLS PREDICT SURVIVAL OF TRIPLE-NEGATIVE BREAST CANCER Syventävien opintojen kirjallinen työ Kevätlukukausi 2020 Hilda Vihervuori TUMOR-INFILTRATING LYMPHOCYTES AND CD8+ T CELLS PREDICT SURVIVAL OF TRIPLE-NEGATIVE BREAST CANCER Kliininen

  2020cites this paper
• Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer

  2019cites this paper
• Immunotherapy and targeted therapy combinations in metastatic breast cancer.

  2019cites this paper
• Association between the elevation of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysis

  2019cites this paper
• Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

  2019cites this paper
• Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

  2019cites this paper
• Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer

  2019cites this paper
• CXCL1 stimulates migration and invasion in ER-negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis

  2019cites this paper
• Immunotherapy in breast cancer

  2019cites this paper
• Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B.

  2019cites this paper
• Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women

  2019cites this paper
• Immunotherapy in breast cancer

  2019cites this paper
• Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer

  2019cites this paper
• Preoperative Therapy for Operable Breast Cancer

  2019cites this paper
• Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric cancer

  2018cites this paper
• Genomic Applications in Breast Carcinoma

  2018cites this paper
• Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67

  2018cites this paper
• Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

  2018cites this paper
• Immunologic Approaches to Breast Cancer Therapy

  2018cites this paper
• A genomic ruler to assess oncogenic transition between breast tumor and stroma

  2018cites this paper
• An Update on Breast Cancer Multigene Prognostic Tests—Emergent Clinical Biomarkers

  2018cites this paper
• Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

  2018cites this paper
• Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

  2018cites this paper
• Immunological differences between primary and metastatic breast cancer

  2018cites this paper
• Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial

  2018cites this paper
• Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer

  2018cites this paper
• Expression de PD-L1 et inhibiteurs de la voie PD-1/PD-L1 dans le cancer du sein

  2018cites this paper
• Prediction of tumor mutation burden in breast cancer based on the expression of er, Pr, her-2, and Ki-67

  2018cites this paper
• [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].

  2018cites this paper
• Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.

  2018cites this paper
• Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer

  2018cites this paper
• Sentinel lymph node B cells can predict disease-free survival in breast cancer patients

  2018cites this paper
• Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer

  2018cites this paper
• Adaptive immunity programmes in breast cancer

  2017cites this paper
• The regulatory role of miRNAs on VDR in breast cancer

  2017cites this paper
• Biomarkers of the PD-1 Pathway in Breast Carcinomas

  2017cites this paper
• Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

  2017cites this paper
• Is complete response the answer?

  2017cites this paper
• Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

  2017cites this paper
• Response to the Letter to the Editor on: "A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets," Cancer Lett. 2016 Nov 28;382(2):203-214.

  2017cites this paper